Predictive factors of acute urinary retention requiring catheterization following 125I prostate brachytherapy

Japanese Journal of Clinical Oncology

Volumn 36, Issue 5, 2006, Pages 285-289

  Ohashi, Toshio ^a   Yorozu, Atsunori ^a   Toya, Kazuhito ^a   Saito, Shiro ^a   Momma, Tetsuo ^a  

^a NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

Author keywords

Brachytherapy; Catheterization; Iodine 125; Prostate cancer; Urinary morbidity

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; TAMSULOSIN;

ADULT; AGED; ARTICLE; BLADDER CATHETERIZATION; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSIMETRY; ECHOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; NEEDLE; ORGAN SIZE; PREDICTION; PROSTATE; PROSTATE CANCER; RADIATION DOSE; RISK ASSESSMENT; TIME; TREATMENT OUTCOME; UNIVARIATE ANALYSIS; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; FORECASTING; GONADOTROPIN-RELEASING HORMONE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOADJUVANT THERAPY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; URINARY CATHETERIZATION; URINARY RETENTION;

EID: 33745686432     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl008     Document Type: Article

References (26)

1. Blasko JC, Grimm PD, Sylvester JE, Badiozamani KR, Hoak D, Kavanagh W. Palladium-103 brachytherapy for prostate carcinoma. Int J Radiat Oncol Biol Phys 2000;46:839-850.
2. Ragde H, Elgamal AA, Snow PB, Brandt J, Bartolucci AA, Nadir BS, et al. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-Gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma [see comments]. Cancer 1998;83:989-1001.
3. Han BH, Demel KC, Wallner K, Ellis W, Young L, Russell K. Patient reported complications after prostate brachytherapy. J Urol 2001;166:953-957.
4. Merrick GS, Butler WM, Lief JH, Dorsey AT. Temporal resolution of urinary morbidity following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;47:121-128.
5. Wust P, von Borczyskowski DW, Henkel T, Rosner C, Graf R, Tilly W, et al. Clinical and physical determinants for toxicity of 125-I seed prostate brachytherapy. Radiother Oncol 2004;73:39-48.
6. 125I brachytherapy of the prostate. BJU Int 2003;92:555-558.
7. Blasko JC, Ragde H, Grimm PD. Transperineal ultrasound-guided implantation of the prostate: Morbidity and complications. Scand J Urol Nephrol Suppl 1991;137:113-118.
8. Kaye KW, Olson DJ, Payne JT. Detailed preliminary analysis of 125-iodine implantation for localized prostate cancer using percutaneous approach. J Urol 1995;153:1020-1025.
9. 103Pd brachytherapy and external beam irradiation for clinically localized, high-risk prostatic carcinoma. Int J Radiat Oncol Biol Phys 1996;35:875-879.
10. Lee N, Wuu CS, Brody R, Laguna JL, Katz AE, Bagiella E, et al. Factors predicting for postimplantation urinary retention after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2000;48:1457-1460.
11. Bucci J, Morris WJ, Keyes M, Spadinger I, Sidhu S, Moravan V. Predictive factors of urinary retention following prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;53:91-98.
12. Salem N, Simonian-Sauve M, Rosello R, Alzieu C, Gravis G, Maraninchi D, et al. Predictive factors of acute urinary morbidity after iodine-125 brachytherapy for localized prostate cancer: A phase 2 study. Radiother Oncol 2003;66:159-165.
13. Kwok Y, DiBiase SJ, Amin PP, Naslund M, Sklar G, Jacobs SC. Risk group stratification in patients undergoing permanent 125I prostate brachytherapy as monotherapy. Int J Radiat Oncol Biol Phys 2002;53:588-594.
14. Toya K, Yorozu A, Ohashi T, Okada M, Itoh R, Monma T, et al. Experience of brachytherapy using I-125 seed permanent implants for localized prostate cancer. Nippon Acta Radiologica 2005;65:432-437.
15. Ohashi T, Yorozu A, Toya K, Saito S, Momma T. Acute urinary morbidity following I-125 prostate brachytherapy. Int J Clin Oncol 2005;10:262-268.
16. Vicini FA, Kini VR, Edmundson G, Gustafson GS, Stromberg J, Martinez A. A comprehensive review of prostate cancer brachytherapy: Defining an optimal technique. Int J Radiat Oncol Biol Phys 1999;44:483-491.
17. Butler WM, Merrick GS, Dorsey AT, Hagedorn BM. Comparison of dose length, area, and volume histograms as quantifiers of urethral dose in prostate brachytherapy. Int J Radiat Oncol Biol Phys 1999;48:1575-1582.
18. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester JE, Hoak DC, et al. Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate cancer. Cancer 1997;80:442-453.
19. Ragde H, Blasko JC, Grimm PD, Kenny GM, Sylvester J, Hoak DC, et al. Brachytherapy for clinically localized prostate cancer: Results at 7 and 8 year follow-up. Semin Surg Oncol 1997;13:438-443.
20. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transprineal I-125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol 1996;14:449-453.
21. Crook J, McLean M, Catton C, Yeung I, Tsihlias J, Pintilie M., et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002;52:453-460.
22. Terk MD, Stock RG, Stone NN. Identification of patients at increased risk for prolonged urinary retention following radioactive seed implantation of the prostate. J Urol 1998;160:1379-1382.
23. Eapen L, Kayser C, Deshaies Y, Perry G, E C, Morash C, Cygler JE, et al. Correlating the degree of needle trauma during prostate brachytherapy and development of acute urinary toxicity. Int J Radiat Oncol Biol Phys 2004;59:1392-1394.
24. 125I prostate brachytherapy. Brachytherapy 2002;1:131-137.
25. Merrick GS, Butler WM, Wallner KE, Murray B, Allen Z, Lief JH, et al. The effect of hormonal manipulation on urinary function following permanent prostate brachytherapy. Brachytherapy 2004; 3:22-29.
26. Keole S, Ben-Josef E, Cher M, Forman JD, Zuniga C, Rosenberg M. et al. Factors predicting acute urinary retention in patients undergoing prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002;54(Suppl.): 258-259.